Oncocyte Corp Files 8-K: Material Agreement, Financials, Equity Sales
Ticker: IMDX · Form: 8-K · Filed: Apr 12, 2024 · CIK: 1642380
Sentiment: neutral
Topics: material-agreement, financial-results, equity-sale
TL;DR
Oncocyte dropped an 8-K detailing a big agreement, financial results, and stock sales. Check it out.
AI Summary
On April 11, 2024, Oncocyte Corporation entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company also reported on its Results of Operations and Financial Condition. Additionally, the filing addresses Unregistered Sales of Equity Securities, includes a Regulation FD Disclosure, and notes Other Events, along with Financial Statements and Exhibits.
Why It Matters
This 8-K filing provides crucial updates on Oncocyte's financial health, strategic agreements, and equity transactions, which are important for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — The filing covers multiple significant events including material agreements, financial results, and equity sales, which can introduce volatility and require careful investor scrutiny.
Key Players & Entities
- Oncocyte Corporation (company) — Registrant
- April 11, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement entered into by Oncocyte Corporation?
The filing indicates the entry into a Material Definitive Agreement on April 11, 2024, but the specific details of this agreement are not provided in the excerpt.
What specific financial information is being disclosed in the Results of Operations and Financial Condition section?
The excerpt states that the filing includes information on Results of Operations and Financial Condition, but the specific financial figures or details are not present in the provided text.
What type of equity securities were sold in the Unregistered Sales of Equity Securities event?
The filing mentions Unregistered Sales of Equity Securities, but the type and details of these securities are not specified in the provided excerpt.
Are there any specific disclosures related to Regulation FD in this filing?
Yes, the filing explicitly lists 'Regulation FD Disclosure' as an item, indicating that the company is providing information in accordance with these regulations.
What are the 'Other Events' mentioned in the 8-K filing?
The filing lists 'Other Events' as a category, but the specific nature of these events is not detailed in the provided text.
Filing Stats: 1,755 words · 7 min read · ~6 pages · Grade level 12.9 · Accepted 2024-04-12 06:04:46
Key Financial Figures
- $0.0001 — Common Stock, with an exercise price of $0.0001 per share. The purchase price for one C
- $2 — purchase price for one Common Share was $2.9164, and the purchase price for one Pr
- $2.9163 — se price for one Pre-Funded Warrant was $2.9163. The closing of the Private Placement i
- $15.8 m — cement are expected to be approximately $15.8 million, before deducting placement agent
- $5 million — ing capital. In addition, approximately $5 million of the proceeds from the Private Placem
Filing Documents
- form8-k.htm (8-K) — 55KB
- ex4-1.htm (EX-4.1) — 114KB
- ex10-1.htm (EX-10.1) — 277KB
- ex10-2.htm (EX-10.2) — 179KB
- ex99-1.htm (EX-99.1) — 11KB
- ex99-2.htm (EX-99.2) — 86KB
- 0001493152-24-014380.txt ( ) — 1024KB
- ocx-20240411.xsd (EX-101.SCH) — 3KB
- ocx-20240411_lab.xml (EX-101.LAB) — 33KB
- ocx-20240411_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On April 12, 2024, the Company issued a press release announcing the Company's financial results for the year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.2, which, in its entirety, is incorporated herein by reference. The information contained in Item 7.01 of this Current Report on Form 8-K is incorporated by reference in this Item 2.02. Item 3.02 Unregistered Sales of Equity Securities. The information contained in Item 1.01 of this Current Report on Form 8-K in relation to (i) the Common Shares and the Pre-Funded Warrants and (ii) the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants, is incorporated herein by reference. Neither the issuance of the Common Shares, the Pre-Funded Warrants or the shares of Common Stock issuable upon exercise thereof, as applicable, were registered under the Securities Act or any state securities laws. The issuance of the Common Shares and the Pre-Funded Warrants were and the shares of Common Stock issuable upon the exercise thereof will be issued in reliance on the exemptions from registration provided by Section 4(a)(2) under the Securities Act and Regulation D promulgated thereunder. Item 7.01 Regulation FD Disclosure The Company provided a corporate presentation to various investors in the Private Placement. A copy of the presentation will be available on the Company's investor relations website at https://investors.oncocyte.com until 5:00PM Eastern Time on April 16, 2024. The information contained in this Item 7.01 is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that Section or Sections 11 and 12(a)(2) of the Securities Act. The information contained in this Item 7.01 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or oth
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ONCOCYTE CORPORATION Date: April 12, 2024 By: /s/ Joshua Riggs Joshua Riggs President and Chief Executive Officer